发布求助
文献互助 智能选刊 最新文献

在BCR:: abl1阴性的b细胞/髓细胞混合表型急性白血病患者中，低强度化学免疫治疗cladribine、低剂量阿糖胞苷、venetoclax和blinatumumab可产生高有效率。

IF 8.2 1区 医学 Q1 HEMATOLOGY
Haematologica Pub Date : 2025-06-26 DOI:10.3324/haematol.2025.287932
Roberta S Azevedo,Wei-Ying Jen,Danielle Hammond,Fadi G Haddad,Alexis Geppner,Ghayas C Issa,Koji Sasaki,Jayastu Senapati,Elias Jabbour,Farhad Ravandi,Hagop Kantarjian,Tapan M Kadia
{"title":"在BCR:: abl1阴性的b细胞/髓细胞混合表型急性白血病患者中，低强度化学免疫治疗cladribine、低剂量阿糖胞苷、venetoclax和blinatumumab可产生高有效率。","authors":"Roberta S Azevedo,Wei-Ying Jen,Danielle Hammond,Fadi G Haddad,Alexis Geppner,Ghayas C Issa,Koji Sasaki,Jayastu Senapati,Elias Jabbour,Farhad Ravandi,Hagop Kantarjian,Tapan M Kadia","doi":"10.3324/haematol.2025.287932","DOIUrl":null,"url":null,"abstract":"Not available.","PeriodicalId":12964,"journal":{"name":"Haematologica","volume":"242 1","pages":""},"PeriodicalIF":8.2000,"publicationDate":"2025-06-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Lower-intensity chemo-immunotherapy with cladribine, low-dose cytarabine, venetoclax and blinatumomab produces high response rates in patients with BCR::ABL1-negative B-cell / myeloid mixed phenotype acute leukemia.\",\"authors\":\"Roberta S Azevedo,Wei-Ying Jen,Danielle Hammond,Fadi G Haddad,Alexis Geppner,Ghayas C Issa,Koji Sasaki,Jayastu Senapati,Elias Jabbour,Farhad Ravandi,Hagop Kantarjian,Tapan M Kadia\",\"doi\":\"10.3324/haematol.2025.287932\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Not available.\",\"PeriodicalId\":12964,\"journal\":{\"name\":\"Haematologica\",\"volume\":\"242 1\",\"pages\":\"\"},\"PeriodicalIF\":8.2000,\"publicationDate\":\"2025-06-26\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Haematologica\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.3324/haematol.2025.287932\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"HEMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Haematologica","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3324/haematol.2025.287932","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

不可用。
本文章由计算机程序翻译，如有差异，请以英文原文为准。
分享
查看原文 本刊更多论文
Lower-intensity chemo-immunotherapy with cladribine, low-dose cytarabine, venetoclax and blinatumomab produces high response rates in patients with BCR::ABL1-negative B-cell / myeloid mixed phenotype acute leukemia.
Not available.
求助全文
通过发布文献求助，成功后即可免费获取论文全文。 去求助
来源期刊
Haematologica
Haematologica 医学-血液学
CiteScore
14.10
自引率
2.00%
发文量
349
审稿时长
3-6 weeks
期刊介绍： Haematologica is a journal that publishes articles within the broad field of hematology. It reports on novel findings in basic, clinical, and translational research. Scope: The scope of the journal includes reporting novel research results that: Have a significant impact on understanding normal hematology or the development of hematological diseases. Are likely to bring important changes to the diagnosis or treatment of hematological diseases.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：604180095
Book学术官方微信